Overview
Liquid biopsy enables genomic analysis from circulating tumor DNA for therapy selection and disease monitoring.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Insufficient tissue ● Treatment monitoring ● MRD ● Recurrence
Applicable Cancer Types
Lung, Breast, Colorectal, Multiple solid tumors
What is Covered?
- SNVs
- InDels
- CNVs
- Fusions
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
Ultra-sensitive cfDNA sequencingkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
Plasma/CSF/Urine |
|
Samples |
10–20 mL blood |
|
Turnaround Time |
~15 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |